Ann: Half Year Report and Appendix 4D 31 December 2024, page-2

Chimeric Therapeutics Limited is pleased to announce its financial results for the half year ended 31 December
2024.
FINANCIAL REVIEW
The group reported a loss for the year ended 31 December 2024 of $ 2,857,887 (31 December 2023: profit of
$2,443,997). The decreased loss relates to the scale-down of headcount, a reduction of general and
administration expenses and reprioritisation of projects.

I remain concerned that no one at CHM appears to review these reports before they are published. In this instance they are not the results for the year - they are the results for the half-year. Secondly it is an increased loss -not a decreased loss so the subsequent explanation provided doesn't make sense without adding in an explanation about the one-off finder fee that boosted the prior year's half year result.

This is not an isolated example. I have raised this with CHM directly previously but it doesn't appear to have resulted in much improvement.

Let's hope they are better at the science then they are at the financial reporting.